Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism

Behavioural Brain Research

Volumn 211, Issue 2, 2010, Pages 236-239

  Schneider, J S ^a   Tinker, J P ^a   Decamp, E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Attention; Clonidine; Cognition; Parkinson; Working memory

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CLONIDINE; IDAZOXAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; MACACA; MEMORY; NONHUMAN; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; SEDATION; TASK PERFORMANCE; WORKING MEMORY;

ADRENERGIC ALPHA-AGONISTS; ANALYSIS OF VARIANCE; ANIMALS; ATTENTION; CLONIDINE; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MACACA FASCICULARIS; MATCHED-PAIR ANALYSIS; MEMORY; PARKINSONIAN DISORDERS; REACTION TIME; STATISTICS, NONPARAMETRIC;

EID: 77952430842     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.03.040     Document Type: Article

References (37)

1. Arnsten A.F.T. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 2006, 67(Suppl. 8):7-12.
2. Arnsten A.F.T., Cai J.X. Postsynaptic alpha-2 receptor stimulation improves memory in aged monkeys: indirect effects of yohimbine versus direct effects of clonidine. Neurobiol Aging 1993, 14:597-603.
3. Arnsten A.F.T., Contant T.A. Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology (Berl.) 1992, 108:159-169.
4. Arnsten A.F.T., Goldman-Rakic P.S. Analysis of alpha-2 adrenergic agonist effects on the delayed nonmatch-to-sample performance of aged rhesus monkeys. Neurobiol Aging 1990, 11:583-590.
5. Arnsten A.F.T., Scahill L., Findling R.L. Alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol 2007, 17:393-406.
6. Baddeley A.D. Working memory 1986, Oxford Univ. Press, New York.
7. Baddeley A.D. Exploring the central executive. Quart J Expt Psychol A 1996, 49:5-28.
8. Baddeley A.D., Hitch G.J.L. Working memory. The psychology of learning and motivation: advances in research and theory 1974, Vol.8:47-89. Academic Press, New York.
9. Brozoski T., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficits caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979, 205:929-931.
10. Buccafusco J.J., Webster S.J., Terry A.V., Kille N., Blessing D. Protracted cognitive effects produced by clonidine in Macaca nemestrina performing a delayed matching task. Psychopharmacology 2009, 202:477-485.
11. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001, 11:1136-1143.
12. Cooper J.A., Sagar H.J., Doherty S.M., Jordan N., Tidswell P., Sullivan E.V. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. Brain 1992, 115:1701-1725.
13. Decamp E., Schneider J.S. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur J Neurosci 2004, 20:1371-1378.
14. Decamp E., Schneider J.S. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. Brain Res 2009, 1262:109-114.
15. Decamp E., Tinker J.P., Schneider J.S. Attentional cueing reverses deficits in spatial working memory task performance in chronic low dose MPTP-treated monkeys. Behav Brain Res 2004, 152:259-262.
16. Desimone R., Duncan J. Neural mechanisms of selective visual attention. Ann Rev Neurosci 1995, 18:193-222.
17. Franowicz J.S., Arnsten A.F.T. Treatment with the noradrenergic alpha-2 agonist clonidine, but not diazepam, improves spatial working memory in normal young rhesus monkeys. Neuropsychopharmacology 1999, 21:611-621.
18. Fukuda K., Vogel E.K. Human variation in overriding attentional capture. J Neurosci 2009, 29:8726-8733.
19. Gevaerd M.S., Miyoshi E., Silveira R., Canteras N.S., Takahashi R.N., Da Cunha C. l-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats. Int J Neuropsycopharmacol 2001, 4:361-370.
20. Gotham A.M., Brown R.G., Marsden C.D. Frontal cognitive function in patients with Parkinson's disease " on" and " off" levodopa. Brain 1988, 111:299-321.
21. Jentsch J.D., Anzivino L.A. A low dose of the alpha 2 agonist clonidine ameliorates the visual attention and spatial working memory deficits produced by phencyclidine administration to rats. Psychopharmacology 2004, 175:76-83.
22. Just M.A., Carpenter P.A. A capacity theory of comprehension: individual differences in working memory. Psychol Rev 1992, 99:122-149.
23. Lange K.W., Robbins T.W., Marsden C.D., James M., Owen A.M., Paul G.M. l-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl.) 1992, 107:394-404.
24. Li B.-M., Mao Z.-M., Wang M., Mei Z.-T. Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacology 1999, 21:601-610.
25. O'Neill J., Fitten L.J., Siembieda D.W., Ortiz F., Halgren E. Effects of guanfacine on three forms of distraction in the aging macaque. Life Sci 2000, 67:877-885.
26. Owen A.M. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 2004, 10:525-537.
27. Riekkinen M., Jakala P., Kejonen K., Riekkinen P. The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease. Neuroscience 1999, 92:983-989.
28. Robbins T.W. The case of frontostriatal dysfunction in schizophrenia. Schizophr Bull 1990, 16:391-402.
29. Robbins T.W. Synthesizing schizophrenia: a bottom-up, symptomatic approach. Schizophr Bull 2005, 31:854-864.
30. Russell V.A. Neurobiology of animal models of attention-deficit hyperactivity disorder. J Neurosci Methods 2007, 161:185-198.
31. Schneider J.S. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively impaired, motor asymptomatic monkeys. Brain Res 1990, 534:25-36.
32. Schneider J.S., Kovelowski C.J. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 1990, 519:122-128.
33. Schneider J.S., Roeltgen D.P. Chronic low dose MPTP-induced cognitive impairment in primates: a possible model for the cognitive disturbances of attention deficit disorders. J Child Neurol 1991, 6:S82-S89.
34. Schneider J.S., Roeltgen D.P. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res 1993, 615:351-354.
35. Schneider J.S., Tinker J.P., Van Velson M., Menzaghi F., Lloyd G.K. The nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low dose MPTP-treated monkeys. J Pharmacol Expt Therapeut 1999, 290:731-739.
36. Swainson R., Rogers R.D., Sahakian B.J., Summers B.A., Polkey C.E., Robbins T.W. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000, 38:596-612.
37. Thomas K.M., King S.W., Franzen P.L., Welsh T.F., Berkowitz A.L., Noll D.C., et al. A developmental functional MRI study of spatial working memory. NeuroImage 1999, 10:327-338.